With 2023 poised to be the year of the adalimumab (Humira, AbbVie) biosimilar wave, a new report focuses on market expansion and sustainability for biosimilars in the United States.
According to the report, issued by Cardinal Health, gastroenterologists appeared to be comfortable with the prospect of prescribing a Humira biosimilar, with 93% saying they were at least somewhat comfortable and 50% very comfortable. Safety and efficacy as well as overall issues with switching were the most often cited concerns.
The first adalimumab biosimilar, adalimumab-atto (Amjevita, Amgen), entered the U.S. market on Jan. 31, after six years of regulatory delay. At least seven more adalimumab biosimilars are expected to debut later this year, likely in July. Clinical and real-world evidence, and patient out-of-pocket cost, could play important roles in further differentiating this potentially crowded market.